logo IDIBELL
Català  |   Castellano  |   English
Search
The InstituteResearchWhat's onPlatformsJoin usTools
 

Infections of the Respiratory Tract and in Immunocompromised Patients

Introduction

This group focuses its research activities in two main areas. On the one hand, in respiratory infections, mainly community-acquired Pneumonia and tuberculosis and, secondly, in infections in the immunocompromised host, including patients with cancer, hematopoietic and solid organ transplant and patients with HIV - AIDS infection. Its research interests focus on epidemiological, clinical, diagnostic, therapeutic and preventive aspects of these infections.



Research lines

Respiratory infections:

  1. Community-acquired Pneumonia
  2.  Influenza
  3. Tuberculosis and other mycobacterial infections

Infections in the immunocompromised host:

  1. Cancer patients and transplant recipients
  2. Patients with HIV infection - AIDS

 


Selected articles (2016)

 

  •    Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O´Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File Jr TM, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight S, Brozek JL. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63: e61-e111.
  •   López-Medrano F, Silva JT, Fernández-Ruiz M, Carver PL, van Delden C, Merino E, Pérez-Saez MJ, Montero M, Coussement J, Mazzolin MA, Cervera C, Santos L, Sabé N, Scemia A, Cordero E, Cruzado-Vega L, Martín PL, Len O, Rudas E, Ponce de León A, Arriola M, Lazurica R, David M, González-Rico C, Henríquez-Palop F, Fortún J, Nucci M, Manuel O, Paño-Pardo JR, Montejo M, Muñoz P, Sánchez-Sobrino B, Mazuecos A, Pascual J, Horcajada J, Lecompte T, Lumbreras C, Moreno A, Carratalà J, Blanes M, Hernández D, Hernández-Mendez EA, Fariñas MC, Perelló-Carrascosa M, Morales JM, Andrés A, Aguado JM. Risk factors for early pulmonary invasive aspergillosis in kidney transplant recipients: results from a multinational matched case-control study. Am J Transpl 2016; 16: 2148-2157.
  • Imaz A, Martinez-Picado J, Niubó J, Kashuba AD, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczer D. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.  J Infect Dis 2016; 214: 1512-1519.
  • Podzamczer D, Imaz A. Dual antiretroviral therapy: finding a place in the battle. Lancet HIV 2016; 3: e335-6.
  • Dinges W, Girard PM, Podzamczer D, Brockmeyer N, Garcían F, Harrer T, Lelievre JD, Frank I, De Verdière NC, Yeni GP, Ortega E, Rubio R, Clotet B, DeJesus E,  Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L,  Bouchaud O, Felizarta F, Meurer A, François Raffi F, Stefan Esser S,  Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F. The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults A Randomized Controlled Trial. Medicine (Baltimore) 2016; 95, 1-10.
  • Saumoy M, Alonso-Villaverde C, Navarro A, Olmo M, Vila R, Maria Ramon J, Yacovo SD, Ferrer E, Curto J, Vernet A, Vila A, Podzamczer D. Randomized trial of a multidisciplinary lifestyle intervention in HIV-infected patients with moderate-high cardiovascular risk.  Atherosclerosis 2016; 246: 301-308
  • Nicolás D, Esteve A, Cuadros A, Campbell CNJ, Tural C, Podzamczer D, Murillas J, Homar F, Segura F, Force L, Vilaró J, Masabeu A, Garcia I, Mercadal J, Montoliu A, Ferrer E, Riera M, Cifuentes C, Ambrosioni J, Navarro G, Manzardo C, Clotet B, Gatell JM,  Casabona J, Miró JM; for the PISCIS Cohort Study Investigators. Safe reduction in CD4 cell count monitoring in stable, virally suppressed patients with HIV infection or HIV/hepatitis C virus coinfection.  Clin Infect Dis 2016; 62: 1578-1585.
  • Tiraboschi JM, Knobel H, Imaz A, Villar J, Ferrer E, Saumoy M, González A, Rozas N, Vila A, Niubó J, Curto J, Podzamczer D. Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily.  Antivir Ther 2016; 21: 359-363. 
  • Simonetti A, Garcia-Vidal C, Viasus D, Garcia-Somoza D, Dorca J, Gudiol F, Carratalà J. Declining mortality among hospitalized patients with community-acquired pneumonia. Clin Microbiol Infect 2016; 22: 567.e1-7.
  • Santín M, Morandeira-Rego F, Alcaide F, Rabuñal R, Anibarro L, Agüero-Balbin R, Casas-Garcia X, Perez-Escolano E, Navarro MD, Sánchez F, Coira-Nieto A, Trigo-Daporta M, Martínez-Meñaca A, Gonzalez-Cuevas A, López-Prieto MD, Domínguez-Castellano A, Jové N, IL-2 Study Team. Detection of interleukin-2 is not useful for distinguishing between latent and active tuberculosis in clinical practice: a prospective cohort study. Clin Microbiol Infect 2016; 22: 1007.e1-1007.e5.
  • Gudiol C, Aguado JM, Carratalà J. Bloodstream infection in patients with solid tumors. VIRULENCE 2016; 7: 298-308.
  • Cuervo G, Garcia-Vidal C, Nucci M, Puchades F, Fernández-Ruiz M, Obed M, Manzur A, Gudiol C, Pemán J, Aguado JM, Ayats J, Carratalà J. Breakthrough candidemia in the era of broad-spectrum antifungal therapies. Clin Microbiol Infect 2016; 22: 181-188.

 

Selected projects

 

  • Estudio de la respuesta inmune y nuevos biomarcadores en pacientes hospitalizados con neumonía adquirida en la comunidad: análisis del perfil de expresión de genes. Investigador principal: Carratalà J. Finançador: ISCIII. Codi: PI14/00580. Duració: 1/1/2015-31/12/2017. Pressupost: 184.827,50€
  • Incidencia, etiología, factores de riesgo y relevancia clínica de los cultivos positivos de los líquidos de preservación de órganos sólidos. Investigador principal: Sabé N. Finançador: ISCIII. Codi: PI14/00935. Duració: 1/1/2015-31/12/2017. Pressupost: 82.885,00€
  • Prevención de la infección del catéter venoso central en pacientes neutropénicos mediante el sellado del catéter con taurolidina: estudio aleatorizado, doble ciego, controlado con placebo. Investigador principal: Gudiol C. Finançador: ISCIII. Codi: PI13/01474. Duració: 1/1/2014-31/12/2017. Pressupost: 126.142,50€
  • Eficacia del biomarcador ARNm-E6/E7 en la detección de lesiones de alto grado y coste-efectividad de un nuevo algoritmo de cribado para cáncer anal en pacientes VIH positivos HSH. Investigador principal: Podzamczer D. Finançador: ISCIII. Codi: PI16/01056. Duració: 1/1/2017-31/12/2019. Pressupost: 214.775,00€
imatge personal
 

Group leader

Jordi Carratalà
Telephone  
+34 932607625
E-mail  
jcarratala@idibell.cat
 
© 2017 Institut d'Investigació Biomèdica de Bellvitge



Results by pageInitial date
Select date
TitleFinal date
Select date
Search


Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept



Your password is about to expire. Please, write in a new password to continue

Remember this password allows you to access to all IDIBELL’s web applications

New password:
Confirm new password:

Accept


Cancell

Passwords doesn’t match
The password must have at least 6 characters
The new password can not contain special characters
User register

Name
Surname
Second Surname
E-mail
User
Password
Language


Accept


Cancell




Encara no heu contestat l'enquesta de satisfacció sobre la píndola formativa sobre patents. No trigareu més de cinc minuts a fer-ho. La vostra opinió és molt important per millorar l’IDIBELL.

Voleu fer l’enquesta ara?

Yes

No




Further personal and contact information is needed to maintain IDIBELL databases.

Do you wish to fill the form now?

Yes

No





Please, remember to introduce your holiday’s planning in the application

Accept

Cancell